Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Westblade LF, Mathison BA, Singer MS, Jerris RC, Caltharp SA. Photo Quiz: A 4-Year-Old Boy Vomits on His Sister. J Clin Microbiol. 2016;54(12):2845.

Yang M, Zu K, Mucci LA, Rider JR, Fiorentino M, Clinton SK, et al. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control. 2016;27(8):1043-7.

Zhang W, Tan AY, Blumenfeld J, Liu G, Michaeel A, Zhang T, et al. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease. Cancer Genet. 2016;209(1-2):11-20.

Reid MD, Basturk O, Shaib WL, Xue Y, Balci S, Choi H-, et al. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. Mod Pathol. 2016;29(10):1243-53.

Hsu Y-, Cushing MM. Autologous Stem Cell Mobilization and Collection. Hematol Oncol Clin North Am. 2016;30(3):573-89.

Goss C, Avecilla ST, Garbaini J, Degtyaryova D, Lo D, Chang DY, et al. Can the interval between antibody identifications be increased for alloimmunized patients? Transfusion. 2016;56(2):334-8.

Lee SS, Tyler JK. Physiology: Stressed-out chromatin promotes longevity. Nature. 2016;534(7609):625-6.

Magro CM, Momtahen S, Verma S, Abraham RM, Friedman C, Nuovo GJ, et al. Cutaneous myeloid dendritic cell dyscrasia: A cutaneous clonal monocytosis associated with chronic myeloproliferative disorders and peripheral blood monocytosis. Ann Diagn Pathol. 2016;25:85-91.

Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, et al. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget. 2016;7(45):72593-72607.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, et al. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2016;22(4):935-47.